The news directly mentions MediWound (NASDAQ:MDWD) and the analyst's Buy rating and $23 price target. This reaffirmation of the Buy rating by HC Wainwright & Co. analyst Swayampakula Ramakanth is likely to have a positive short-term impact on the stock price, as it signals confidence in the company's prospects.